Abstract
Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.
Original language | English |
---|---|
Pages (from-to) | 1207-1217 |
Number of pages | 11 |
Journal | Expert Opinion on Therapeutic Targets |
Volume | 11 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2007 Sept |
Externally published | Yes |
Keywords
- Angiogenesis
- Metastasis
- Protein tyrosine kinase
- Src family kinase
- Tumor progression
- Tyrosine kinase inhibitors
- VEGF
- Vascular permeability
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
- Clinical Biochemistry